L'atazanavir (BMS-232632) est un nouvel inhibiteur de la protéase qui est en voie de développement chez Bristol-Myers Squibb. La plupart des inhibiteurs de la protéase (IP) actuellement disponibles font augmenter les taux de lipides – cholestérol et triglycérides – chez les PVVIH/sida qui les utilisent. L'atazanavir offre plusieurs avantages comparativement aux IP actuellement sur le marché, dont :
Tout comme l'IP ritonavir (Norvir), il est possible que l'atazanavir ait la faculté d'accroître le niveau sanguin d'autres IP, dont :
L'un des inconvénients possibles de l'atazanavir réside dans le fait qu'il risque d'accroître le taux de bilirubine, un produit de dégradation qui se trouve dans le sang. L'effet à long terme d'une hausse du taux de bilirubine n'est pas clair.
20020131
CATF12411
Copyright © 2002 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.